home / stock / pcvx / pcvx quote
Last: | $75.45 |
---|---|
Change Percent: | 0.2% |
Open: | $71.49 |
Close: | $75.45 |
High: | $75.83 |
Low: | $71.1525 |
Volume: | 1,140,720 |
Last Trade Date Time: | 05/16/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$75.45 | $71.49 | $75.45 | $75.83 | $71.1525 | 1,140,720 | 05-16-2024 |
$71.63 | $68.88 | $71.63 | $71.71 | $68.61 | 689,074 | 05-15-2024 |
$67.33 | $66.15 | $67.33 | $67.5 | $65.87 | 321,300 | 05-14-2024 |
$65.7 | $65.1 | $65.7 | $65.77 | $64.76 | 491,979 | 05-13-2024 |
$65.19 | $65.2 | $65.19 | $66.71 | $64.76 | 533,487 | 05-10-2024 |
$65.57 | $65 | $65.57 | $66.48 | $63.63 | 919,834 | 05-09-2024 |
$66.79 | $66.45 | $66.79 | $68.22 | $65.81 | 467,620 | 05-08-2024 |
$67.52 | $66.4 | $67.52 | $67.755 | $65.86 | 556,995 | 05-07-2024 |
$66.4 | $65.41 | $66.4 | $66.85 | $65.315 | 505,234 | 05-06-2024 |
$65.96 | $66.48 | $65.96 | $67.08 | $65.46 | 620,649 | 05-03-2024 |
$64.55 | $63.83 | $64.55 | $64.9983 | $63.11 | 503,114 | 05-02-2024 |
$63.71 | $60.76 | $63.71 | $64.24 | $60.21 | 765,829 | 05-01-2024 |
$60.55 | $60.61 | $60.55 | $61.195 | $58.84 | 445,654 | 04-30-2024 |
$61.03 | $61.07 | $61.03 | $62.285 | $60.72 | 500,655 | 04-29-2024 |
$60.72 | $60.32 | $60.72 | $60.945 | $59.41 | 594,302 | 04-26-2024 |
$60.06 | $59.59 | $60.06 | $60.09 | $58.1 | 1,566,189 | 04-25-2024 |
$60.3 | $61.05 | $60.3 | $61.98 | $59.97 | 667,923 | 04-24-2024 |
$60.88 | $61.79 | $60.88 | $62.56 | $60.83 | 663,706 | 04-23-2024 |
$61.6 | $61.47 | $61.6 | $63.22 | $60.91 | 627,167 | 04-22-2024 |
$60.83 | $60.46 | $60.83 | $61.92 | $59.39 | 1,344,223 | 04-19-2024 |
News, Short Squeeze, Breakout and More Instantly...
Vaxcyte Inc. Company Name:
PCVX Stock Symbol:
NASDAQ Market:
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 In...
2024-04-23 18:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
The global market study pneumococcal conjugate (PCV) market is ~$8 billion per year, and Vaxcyte Inc (NASDAQ:PCVX) estimates it will grow...